Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292584 | 0.98 | PPIA (0.33) | PPIAGRIN2BGRIN2CUSP2SMN1; SMN2 | |
| SCHEMBL27378855 | 0.82 | PPIA (0.38) | PPIAGRIN2BGRIN2CUSP2SMN1; SMN2 | |
| SCHEMBL1308841 | 0.77 | PPIA (0.33) | PPIAUSP2SMN1; SMN2TSHRPOLB | |
| SCHEMBL3592215 | 0.75 | CYP4F2 (0.36) | CYP4F2CYP4A11 | |
| SCHEMBL5206583 | 0.75 | ALDH1A1 (0.33) | TSHRPOLB | |
| SCHEMBL3293515 | 0.74 | NCF1 (0.34) | PPIAOPRM1OPRL1CYP4F2CYP4A11 | |
| SCHEMBL3295941 | 0.74 | MEN1 (0.36) | USP2SMN1; SMN2OPRM1OPRL1HPGD | |
| SCHEMBL21265902 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2OPRM1POLB | |
| SCHEMBL28247545 | 0.74 | HPGD (0.34) | PPIAUSP2SMN1; SMN2TSHRPOLB | |
| SCHEMBL17154903 | 0.74 | OPRL1 (0.34) | PPIASMN1; SMN2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737163-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7705020-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7595329-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | PPIA 2864/4885GRIN2B 193/4885GRIN2C 392/4885 |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | PPIA 2864/4885GRIN2B 193/4885GRIN2C 392/4885 |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | PPIA 2864/4885GRIN2B 193/4885GRIN2C 392/4885 |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | HRH2, HRH4, GPR4 | PPIA 2830/4885GRIN2B 194/4885GRIN2C 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.